HedgePath Pharmaceuticals Announces Notice of Allowance with Additional Claims Governing the Use of SUBA®-Itraconazole for the Treatment of Lung Cancer

Author's Avatar
May 29, 2019
Article's Main Image

New method of use claims in lung cancer enhance HedgePath's intellectual property estate relating to SUBA-Itraconazole

PR Newswire